| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hui Wu, Chunhua Sui, Hui Xu, Fangzhen Xia, Hualing Zhai, Huixin Zhang, Pan Weng, Bing Han, Sichun Du, Yingli L. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp. Journal of diabetes research. vol 2014. 2015-07-07. PMID:25580440. |
glucagon-like peptide-1 (glp-1) analogues (e.g., exenatide) increase insulin secretion in diabetes but less is known about their effects on glucose production or insulin-stimulated glucose uptake in peripheral tissues. |
2015-07-07 |
2023-08-13 |
rat |
| A J Schee. [Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors]. Revue medicale de Liege. vol 70. issue 4. 2015-07-07. PMID:26054173. |
the endocrine and metabolic effects of albiglutide are similar to those of other glp-1 receptor agonists: stimulation of insulin secretion (incretin effect) and inhibition of glucagon secretion, both in a glucose-dependent manner, retardation of gastric emptying and increase of satiety. |
2015-07-07 |
2023-08-13 |
Not clear |
| Jorinde A W Polderman, Peter L Houweling, Markus W Hollmann, J Hans DeVries, Benedikt Preckel, Jeroen Hermanide. Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial. BMC anesthesiology. vol 14. 2015-07-06. PMID:25419179. |
study protocol of a randomised controlled trial comparing perioperative intravenous insulin, gik or glp-1 treatment in diabetes-pilgrim trial. |
2015-07-06 |
2023-08-13 |
Not clear |
| Jorinde A W Polderman, Peter L Houweling, Markus W Hollmann, J Hans DeVries, Benedikt Preckel, Jeroen Hermanide. Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial. BMC anesthesiology. vol 14. 2015-07-06. PMID:25419179. |
glp-1 increases insulin and decreases glucagon secretion in a glucose-dependent manner, resulting in glucose lowering action with a low incidence of hypoglycaemia. |
2015-07-06 |
2023-08-13 |
Not clear |
| Sarah Farr, Christopher Baker, Mark Naples, Jennifer Taher, Jahangir Iqbal, Mahmood Hussain, Khosrow Adel. Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis. Arteriosclerosis, thrombosis, and vascular biology. vol 35. issue 5. 2015-07-03. PMID:25675997. |
in addition to enhancing insulin secretion, peripheral glucagon-like peptide-1 (glp-1) receptor stimulation has the added benefit of reducing this chylomicron overproduction in patients with type 2 diabetes mellitus. |
2015-07-03 |
2023-08-13 |
Not clear |
| Sri Harsha Tella, Marc S Rendel. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Therapeutic advances in endocrinology and metabolism. vol 6. issue 3. 2015-07-03. PMID:26137215. |
when oral agents fail to control glucose levels in type 2 diabetes, there is a choice between long-acting insulin and glp-1 agonists as additional treatments. |
2015-07-03 |
2023-08-13 |
Not clear |
| Sri Harsha Tella, Marc S Rendel. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Therapeutic advances in endocrinology and metabolism. vol 6. issue 3. 2015-07-03. PMID:26137215. |
patients lose weight with glp-1 treatment and gain weight on insulin. |
2015-07-03 |
2023-08-13 |
Not clear |
| Sri Harsha Tella, Marc S Rendel. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Therapeutic advances in endocrinology and metabolism. vol 6. issue 3. 2015-07-03. PMID:26137215. |
insulin dosing is flexible while glp-1 agents have historically been administered at fixed dosages. |
2015-07-03 |
2023-08-13 |
Not clear |
| Sri Harsha Tella, Marc S Rendel. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Therapeutic advances in endocrinology and metabolism. vol 6. issue 3. 2015-07-03. PMID:26137215. |
now, the use of combined long-acting insulin and glp-1 agonists is promising a major therapeutic change. |
2015-07-03 |
2023-08-13 |
Not clear |
| Sri Harsha Tella, Marc S Rendel. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Therapeutic advances in endocrinology and metabolism. vol 6. issue 3. 2015-07-03. PMID:26137215. |
combined therapy takes advantage of the benefits of both insulin and glp-1 agents. |
2015-07-03 |
2023-08-13 |
Not clear |
| Chiranjib Chakraborty, Minna J Hsu, Govindasamy Agoramoorth. Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A. Cell biochemistry and biophysics. vol 70. issue 2. 2015-07-02. PMID:24809328. |
intestine hormone glucagon-like peptide-1 (glp-1) has an antidiabetic role that enhances insulin secretion and pancreatic β-cell proliferation. |
2015-07-02 |
2023-08-13 |
Not clear |
| Hitomi Oda, Akihiro Mori, Peter Lee, Kaori Saeki, Toshiro Arai, Toshinori Sak. Preliminary study characterizing the use of sitagliptin for glycemic control in healthy Beagle dogs with normal gluco-homeostasis. The Journal of veterinary medical science. vol 76. issue 10. 2015-07-02. PMID:24931645. |
sitagliptin is a dipeptidyl peptidase-4 inhibitor aimed at treating type 2 diabetes mellitus (t2dm) and t1dm, by increasing blood levels of glucagon-like peptide 1 (glp-1) and insulin. |
2015-07-02 |
2023-08-13 |
Not clear |
| Vishal J Patel, Amit A Joharapurkar, Gaurang B Shah, Mukul R Jai. Effect of GLP-1 based therapies on diabetic dyslipidemia. Current diabetes reviews. vol 10. issue 4. 2015-07-01. PMID:24998439. |
consumption of food or glucose stimulates synthesis and secretion of glp-1 in the bloodstream, which in turn stimulates insulin secretion from pancreas and delays gastric emptying. |
2015-07-01 |
2023-08-13 |
Not clear |
| Jennifer M Trujillo, Wesley Nuffe. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. vol 34. issue 11. 2015-07-01. PMID:25382096. |
because of their advantages and unique mechanism of action, glp-1 ras are currently being studied in new clinical areas, including in combination with basal insulin, as adjunctive therapy in type 1 diabetes, and for weight loss. |
2015-07-01 |
2023-08-13 |
Not clear |
| Jennifer M Trujillo, Wesley Nuffe. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. vol 34. issue 11. 2015-07-01. PMID:25382096. |
lixisenatide is a once-daily glp-1 ra that targets postprandial glucose and may be most useful when added to basal insulin as an alternative to rapid-acting insulin. |
2015-07-01 |
2023-08-13 |
Not clear |
| Emanuel Monteiro Candeias, Inês Carolina Sebastião, Susana Maria Cardoso, Sónia Catarina Correia, Cristina Isabel Carvalho, Ana Isabel Plácido, Maria Sancha Santos, Catarina Resende Oliveira, Paula Isabel Moreira, Ana Isabel Duart. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World journal of diabetes. vol 6. issue 6. 2015-07-01. PMID:26131323. |
as glp-1 receptors (glp-1r) are expressed throughout the central nervous system and glp-1 may cross the blood-brain-barrier, an emerging hypothesis suggests that they may be promising therapeutic targets against brain dysfunctional insulin signaling-related pathologies. |
2015-07-01 |
2023-08-13 |
Not clear |
| Emanuel Monteiro Candeias, Inês Carolina Sebastião, Susana Maria Cardoso, Sónia Catarina Correia, Cristina Isabel Carvalho, Ana Isabel Plácido, Maria Sancha Santos, Catarina Resende Oliveira, Paula Isabel Moreira, Ana Isabel Duart. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World journal of diabetes. vol 6. issue 6. 2015-07-01. PMID:26131323. |
importantly, glp-1 actions depend not only on the direct effect mediated by its receptor activation, but also on the gut-brain axis involving an exchange of signals between both tissues via the vagal nerve, thereby regulating numerous physiological functions (e.g., energy homeostasis, glucose-dependent insulin secretion, as well as appetite and weight control). |
2015-07-01 |
2023-08-13 |
Not clear |
| Jeffrey Gagnon, Laurie L Baggio, Daniel J Drucker, Patricia L Brubake. Ghrelin Is a Novel Regulator of GLP-1 Secretion. Diabetes. vol 64. issue 5. 2015-06-29. PMID:25412624. |
glp-1 is a gastrointestinal l-cell hormone that enhances glucose-stimulated insulin secretion. |
2015-06-29 |
2023-08-13 |
mouse |
| Jeffrey Gagnon, Laurie L Baggio, Daniel J Drucker, Patricia L Brubake. Ghrelin Is a Novel Regulator of GLP-1 Secretion. Diabetes. vol 64. issue 5. 2015-06-29. PMID:25412624. |
the intraperitoneal injection of ghrelin into mice 15 min before the administration of oral glucose enhanced glucose-stimulated glp-1 release and improved glucose tolerance, whereas the ghrelin receptor antagonist d-lys ghrp-6 reduced plasma levels of glp-1 and insulin and diminished oral glucose tolerance. |
2015-06-29 |
2023-08-13 |
mouse |
| Mohamed Lotfy, Jaipaul Singh, Hameed Rashed, Saeed Tariq, Erika Zilahi, Ernest Adeghat. The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms. Cell and tissue research. vol 358. issue 2. 2015-06-25. PMID:25115772. |
glp-1 (10(-12)-10(-6) m) induced significant (p < 0.01) dose-dependent increases in insulin release from the pancreas of normal and diabetic rats compared to basal. |
2015-06-25 |
2023-08-13 |
rat |